Abstract
AbstractBispecific antibodies are monoclonal antibodies targeting both a surface molecule on the malignant plasma cells and CD3 on T cells, leading to tumor cell death by activated T cells. Bispecific antibodies targeting B-cell maturation antigen, GPRC5D or FcRH5, demonstrated promising efficacy with favorable safety profile in patients with triple-class refractory multiple myeloma. This novel immunotherapeutic modality will likely change the treatment paradigm in the coming years.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.